Stefan Woll
Mainz, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies.
Journal: Therapeutic advances in medical oncology
Published: October 06, 2025
Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors.
Journal: Journal for immunotherapy of cancer
Published: September 07, 2025
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Journal: Oncoimmunology
Published: October 20, 2023
The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Journal: Journal of translational medicine
Published: June 23, 2023
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer.
Journal: Immunity
Published: May 24, 2023
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation.
Journal: Oncotarget
Published: November 14, 2019
Characterization of zolbetuximab in pancreatic cancer models.
Journal: Oncoimmunology
Published: April 23, 2018
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Journal: International journal of cancer
Published: October 11, 2013
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
Journal: International journal of cancer
Published: May 17, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026